Welcome to our dedicated page for Atara Biotherapeutics news (Ticker: ATRA), a resource for investors and traders seeking the latest updates and insights on Atara Biotherapeutics stock.
Atara Biotherapeutics, Inc (Symbol: ATRA) is a pioneering company in the healthcare sector, specializing in the development of transformative therapies for patients combating serious diseases, including cancer, kidney disease, and autoimmune disorders. Founded in August 2012, Atara Biotherapeutics is driven by a mission to provide better treatment options for patients, inspired by Atara Ciechanover, who tragically passed away from cancer in 2012.
The company's research is founded on groundbreaking discoveries related to activin, myostatin, and other growth factors that can alter disease progression. Atara's innovative approach has led to the development of several promising product candidates:
- Pinta 745
- STM 434
- ATA 842
Moreover, Atara Biotherapeutics is collaborating with the prestigious Memorial Sloan Kettering Cancer Center (MSK) to develop three cutting-edge T-cell product candidates:
- Epstein-Barr Virus (EBV)-targeted Cytotoxic T Lymphocytes (CTLs)
- Cytomegalovirus (CMV)-targeted CTLs
- Wilms Tumor 1 (WT1)-targeted CTLs
These T-cell therapies are designed to tackle the underlying mechanisms of various diseases, offering hope for conditions that are currently challenging to treat.
Atara's product pipeline also includes Tab-cel, ATA188, and ATA3219 (CAR T platform). Each of these candidates targets specific mechanisms of disease, aiming to provide effective and innovative treatment solutions.
The company operates within the US healthcare sector, managing its business as a single operating and reportable segment focused on therapeutic development. Atara Biotherapeutics continues to make strides in its mission, marked by recent achievements and partnerships that underscore its commitment to improving patient outcomes.
Stay updated with the latest news and developments from Atara Biotherapeutics to gain insights into their ongoing projects and performance in the stock market.
Atara Biotherapeutics (Nasdaq: ATRA), a leader in T-cell immunotherapy, has granted 3,700 restricted stock units to a newly hired employee. This inducement grant, approved by the Compensation Committee and made under the company's 2018 Inducement Plan, is in accordance with Nasdaq Listing Rule 5635(c)(4). The grant date is September 3, 2024.
The restricted stock units have a four-year vesting schedule: 25% vests on the first quarterly vesting date after the first anniversary, with the remaining 75% vesting in 12 approximately equal quarterly installments over the following three years. Vesting is subject to continuous employment with Atara.
Atara Biotherapeutics (Nasdaq: ATRA), a leader in T-cell immunotherapy, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The company's Executive Vice President and Chief Scientific & Technical Officer, Cokey Nguyen, Ph.D., will present on Monday, September 9, 2024, at 6:30 a.m. PDT / 9:30 a.m. EDT.
Atara specializes in developing transformative therapies for patients with cancer and autoimmune diseases using its novel allogeneic Epstein-Barr virus (EBV) T-cell platform. Investors and interested parties can access a live webcast of the presentation through the Investors and Media section of atarabio.com. An archived replay will be available on the company's website for 30 days following the live presentation.
Atara Biotherapeutics (Nasdaq: ATRA) has announced a $36 million registered direct offering of common stock and pre-funded warrants. The offering, priced at $8.25 per share, represents a 15% premium to Atara's 7-day volume-weighted average price. Participants include existing top institutional investors and a new strategic investor from a large public biotechnology company. The proceeds will extend Atara's cash runway into 2027, supporting the U.S. BLA approval for tab-cel® and advancement of ATA3219. Greg Ciongoli, founder of Adiumentum Capital Management, will join Atara's Board of Directors. The offering is expected to close around September 5, 2024, subject to customary conditions.
Atara Biotherapeutics (Nasdaq: ATRA) reported Q2 2024 financial results and operational progress. Key highlights include:
1. Tab-cel® U.S. BLA accepted under Priority Review with PDUFA date of January 15, 2025.
2. ATA3219 studies in Lupus Nephritis and Severe Systemic Lupus Erythematosus to start Q4 2024; initial data expected mid-2025.
3. ATA3219 Non-Hodgkin's Lymphoma study enrolling; initial data expected Q1 2025.
4. Leadership changes: Pascal Touchon to become Chairman, Cokey Nguyen to be appointed President and CEO effective September 9, 2024.
5. Q2 2024 revenues: $28.6 million; net loss: $19.0 million ($3.10 per share).
6. Cash runway extended into 2027, enabling key pipeline readouts.
Atara Biotherapeutics (Nasdaq: ATRA), a leader in T-cell immunotherapy, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The event is scheduled for August 14, 2024, at 8:30 a.m. PDT / 11:30 a.m. EDT.
Pascal Touchon, President and CEO, and Dr. Cokey Nguyen, Executive VP and Chief Scientific & Technical Officer, will represent the company. Atara specializes in developing transformative therapies for cancer and autoimmune diseases using its novel allogeneic Epstein-Barr virus (EBV) T-cell platform.
A live webcast of the presentation will be available on the Investors and Media section of atarabio.com, with an archived replay accessible for 30 days following the event.
Atara Biotherapeutics (Nasdaq: ATRA) announced that the U.S. FDA has accepted and granted Priority Review for the Biologics License Application (BLA) of tabelecleucel (tab-cel®) for treating Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD). The PDUFA target action date is set for January 15, 2025. If approved, tab-cel would be the first therapy in the U.S. for this indication.
The BLA acceptance triggers a $20 million milestone payment from Pierre Fabre Laboratories, with an additional $60 million milestone if approved by the FDA. The application is supported by data from over 430 patients, including the pivotal ALLELE study, which showed a statistically significant 48.8% Objective Response Rate. Tab-cel has already received marketing authorization in Europe, the UK, and Switzerland under the brand name Ebvallo™.
Atara Biotherapeutics (Nasdaq: ATRA), a leader in T-cell immunotherapy, announced the grant of 2,200 restricted stock units to a newly hired employee. This grant, approved by Atara's Board of Directors Compensation Committee, falls under the 2018 Inducement Plan in line with Nasdaq Listing Rule 5635(c)(4). The grant date is set for July 1, 2024, with the units vesting over four years. The first 25% will vest on the first quarterly vesting date following the first anniversary of the vesting commencement date. The remaining units will vest quarterly over the next three years, contingent on continuous employment with Atara. This disclosure complies with Nasdaq Listing Rule 5635(c)(4).
Atara Biotherapeutics (Nasdaq: ATRA) will participate in the Stifel Virtual Cell Therapy Forum, showcasing its innovative T-cell immunotherapy platform. Pascal Touchon, CEO, will present a fireside chat on July 9, 2024, at 6:45 a.m. PDT / 9:45 a.m. EDT. The discussion will be available via live webcast on the company's website, with a replay accessible for 30 days post-event. Atara leverages its allogeneic EBV T-cell platform to develop treatments for cancer and autoimmune diseases.
Atara Biotherapeutics announced that its product Ebvallo™ (tabelecleucel or tab-cel®) has won the 2024 Prix Galien International Award for Best Product for Orphan/Rare Diseases. Ebvallo, developed in collaboration with Pierre Fabre Laboratories, is the first and only approved therapy in Europe for adults and children with EBV+ post-transplant lymphoproliferative disease (PTLD). This prestigious award is often compared to the Nobel Prize in biopharmaceutical research.
Ebvallo received European marketing authorization in December 2022, and Atara submitted a Biologics License Application to the U.S. FDA in May 2024. EBV+ PTLD is a rare and potentially fatal condition affecting transplant patients, with poor survival rates for those who have relapsed or are refractory to prior treatments. The award underscores the innovative and potentially life-saving nature of Ebvallo.
Atara Biotherapeutics (Nasdaq: ATRA) announced a 1-for-25 reverse stock split, effective June 20, 2024, to regain Nasdaq compliance and enhance share value. This split reduces the outstanding common stock from 122,606,575 shares to 4,904,263 shares. It does not impact authorized shares or par value. Adjustments will be made to equity awards and incentive plans. Stockholders will automatically see adjustments in their brokerage accounts, while those holding certificates will receive instructions from Computershare Trust Company. Fractional shares will be compensated in cash.
FAQ
What is the current stock price of Atara Biotherapeutics (ATRA)?
What is the market cap of Atara Biotherapeutics (ATRA)?
What does Atara Biotherapeutics, Inc specialize in?
When was Atara Biotherapeutics founded?
Who is Atara Ciechanover?
What are some of Atara's key product candidates?
With which institution is Atara Biotherapeutics collaborating?
What types of T-cell therapies is Atara developing?
What is the mission of Atara Biotherapeutics?
Where does Atara Biotherapeutics operate?
What are activin and myostatin in the context of Atara's research?
How does Atara manage its business operations?
